Overview of Dr. Mishra
Dr. Asmita Mishra is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from St. George's University School of Medicine and has been in practice 10 years. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 50 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Louisville School of MedicineResidency, Internal Medicine, 2007 - 2010
St. George's University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
- Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
- Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
- Join now to see all
Publications & Presentations
PubMed
- 63 citationsEprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.Asmita Mishra, Roni Tamari, Amy E DeZern, Michael T Byrne, Mahasweta Gooptu
Journal of Clinical Oncology. 2022-12-01 - 11 citationsGilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of.Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh
Journal of Clinical Oncology. 2024-05-20 - 60 citationsBiologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplas...Ryotaro Nakamura, Wael Saber, Michael Martens, Alyssa Ramirez, Bart L. Scott
Journal of Clinical Oncology. 2021-06-09
Abstracts/Posters
- Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts OutcomeAsmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationAsmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell TransplantationAsmita Mishra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021- Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13th, 2021
- Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AMLJuly 21st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
